Abstract
Amplification of the proto-oncogene c-erbB-2 (HER-2/neu) has been shown to be a prognostic marker in ovarian cancer. In order to obtain further information on the biological role of the c-erbB-2 gene product p185 it is necessary to quantify expression levels. In this study we evaluated an enzyme-linked immunosorbant assay (ELISA) for the extracellular domain of p185 to determine whether a soluble oncoprotein fragment can be detected in the serum of ovarian cancer patients and in the serum of pregnant women. Sera from 199 women (57 previously untreated ovarian cancer patients, 62 pregnant women and 80 healthy controls) were assaved in a sandwich ELISA utilizing two mouse monoclonal antibodies. To study c-erbB-2 overexpression in ovarian cancer tissue samples we have used an immunohistochemical technique involving a monoclonal antibody specifically reactive with the external domain of the protein p185. The mean serum value for the normal controls was 1203 HNU/ml with a standard deviation (SD) or 279 HNU/ml and a range of 595–1947 HNU/ml. We chose a level of 1761 HNU/ml (2 SD above the mean) as a cut-off to distinguish individuals with elevated levels. The ovarian cancer patients' serum values ranged from 526 to 16 332 HNU/ml. Immunohistochemically detectable p185 was noted in 8 of 57 ovarian cancer patients. The oncoprotein fragment levels in the sera from these 8 patients ranged from 878 to 16 332 HNU/ml. Of 8 patients with p185 overexpression in their tumors, 4 had elevated serum levels. In the sera from the 49 cancer patients without overexpression the values were distributed in the range 526–2892 HNU/ml. There was no association between serum oncoprotein fragment levels and tumor stage, histological type or grading. Serum concentrations of the p185 fragment in pregnancy ranged from 612 to 3265 HNU/ml. The highest levels were found in the third trimester. The results of the present study raise the possibility that the soluble c-erbB-2 protein level in serum is an indicator for cell proliferation and therefore deserves further evaluation as a diagnostic tool in ovarian cancer patients and pregnancy.
This is a preview of subscription content, log in via an institution to check access.
References
Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dogde R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast RC (1990). Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087–4091
Broders AC (1926) Carcinoma: grading and practical application. Arch Pathol 2:376–381
Carney WP, Hamer PJ, Petit D, Retos C, Greene R, Zabrecky JR, McKenzie S, Hayes S, Kufe D, DeLellis R, Naber R, Wolfe H (1991) Detection and quantification of the human neu protein. J Tumor Marker Oncol 6:53–72
Coussens L, Yang-Feng TL, Liao JC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Franke U, Levinson A, Ullrich A (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139
Haldane JS, Hird V, Hughes CM, Gullick JW (1990) c-erbB-2 oncogene expression in ovarian cancer. J Pathol 162:231–237
Hendler FJ, Ozanne BW (1984) Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest 74:647–651
Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577–580
King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974–976
Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, Schauer A (1993) Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients. J Cancer Res Clin Oncol 119:249–252
Marx D, Schauer A, Reiche C, May A, Ummenhofer AL, Reles A, Rauschecker H, Sauer R, Schumacher M (1990) c-erbB-2-expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 116:15–20
Meden H, Marx D, Hammadi H, Schauer A, Kuhn W (1991) c-erbB-2-Onkogenüberexpression beim Ovarialkarzinom — Prognostische Bedeutung und Korrelation mit klinischen Befunden bei 119 Patientinnen. Verh Dtsch Ges Pathol 75:341
Meden H, Marx D, Hammadi H, Reles A, Rath W, Schauer A, Kuhn W (1992a) Immunohistochemically detected oncoprotein p185/NEU in ovarian cancer: a new prognostic factor? In: Klapdor R (ed) Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties. Zuckschwerdt, München Bern Berlin, pp 431–432
Meden H, Rath W, Marx D, Tsikuras P, Kuhn W, Schauer A (1992b) Mammakarzinom in der Schwangerschaft. Klinische, histologische und immunhistochemische Befunde. Zentralbl Chir 117:216–219
Meden H, Marx D, Rath W, Kuhn W, Hinney B, Schauer A (1992c) c-erb-B-2-Onkogenüberexpression bei primären Ovarialkarzinomen: Häufigkeit und prognostische Bedeutung bei 243 Patientinnen. Geburtshilfe Frauenheilkd 52:667–673
Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, Hinney B, Kuhn W, Schauer A (1994) Overexpression of the oncogene c-erbB-2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 13 (in press)
Mori S, Mori Y, Mukaiyama T, Yamada Y, Sonobe Y, Matsushita H, Sakamoto G, Akiyama T, Ogawa M, Shiraishi M, Toyshima K, Yamamoto T (1990) In vitro and in vivo release of solubleerbB-2 protein from human carcinoma cells. Jpn J Cancer Res 81:489–494
Nadji JD, Morales AR (1984) Immunoperoxidase. II. Practical applications. Lab Med 15:33–37
Paik A, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman A, King CR (1990) Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erb-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103–112
Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd O (1993) Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol 168:162–169
Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL (1987) Epidermal-growth-factor receptor status as a predictor of early recurrence and of death from breast cancer. Lancet I:1398–1402
Schauer A, Marx D, Lipp I, Schumacher M, Sauerbrei W, Rauschecker H, Sauer H (1992a) Diagnostic tools and prognostic factors in human breast cancer evaluated by morphological and immunohistochemical methods. In: Dogliotti L, Sapino A, Bussolati G (eds) Breast cancer: biological and clinical progress. Kluwer Academic, Dordrecht, pp 255–276
Schauer A, Marx D, Kuhn W, Meden H, Rauschecker H, Sauer R, Schumacher M, Sauerbrei W (1992b) Immunhistochemische Tumordiagnostik in der Gynäkologie. In: Kindermann G, Lampe G (Hrsg) Immunhistochemische Diagnostik gynäkologischer Tumoren. Thieme, Stuttgart, pp 41–86
Schauer A, Marx D, Lipp I, Meden H, Schumacher M, Sauerbrei W, Sauer R, Rauschecker H (1992c) Clinical and scientific aspects of oncogene in malignant epithelial tumors. In: Jonat W, Löning R (eds) Clinical and scientific aspects of HER-2/neu/erbB-2. Springer, Heidelberg, pp 111–139
Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA, (1984) Theneu oncogene: anerb-B-related gene encoding a 185.000-M tumour antigen. Nature 312:513–516
Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A, Coussens L (1985) Theneu gene: anerbB-homologous gene distinct from and unlinked to the encoding EGF receptor. Science 229:974–976
Serov SF, Scully RE, Sobin LH (1973) Histological typing of ovarian tumors. In: International histological classification of tumors. 9. WHO, Geneva, pp 37–42
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712
Sternberger LA, Hardy PH, Cuculis JJ, Meyer HG (1970) the unlabeled antibody-enzyme method of immunohistochemistry. Preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-anti-peroxidase) and its use in identification of spirochetes. J Histochem Cytochem 18:315–333
Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL (1989) HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7:1120–1128
Waldmann TA, Longo DL, Leonhard WJ, Depper JM, Thompson CB, Kroenke M, Goldman CK, Sharrow S, Bongiovanni K, Greene WC (1985) Interleukin-2 receptor expression in HZLV-1-associated T-cell leukemia. Cancer Res 45:4559–4562
Yamamoto T, Shantard I, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K (1986) Anerb-B-related gene c-erbB-2 encodes a possible receptor protein similar to the epidermal growth factor receptor. Nature 319:230–234
Zabrecky JR, Lam T, McKenzie SJ, Cerney W (1991) The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells. SK-BR-3. J Biol Chem 266:1716–1720
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meden, H., Marx, D., Fattahi, A. et al. Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. J Cancer Res Clin Oncol 120, 378–381 (1994). https://doi.org/10.1007/BF01247465
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01247465